Pillar Biosciences OncoReveal Nexus/MSK-REACT
Pillar Biosciences has launched OncoReveal Nexus, a research-use-only next-generation sequencing-based targeted cancer panel kit. The panel assesses key driver genes for both hematological and solid tumors and is fully automatable, batching up to 81 patient samples in an Illumina MiSeq run, using as little as 2.5 ng DNA per sample. Reports are issued two to three days after DNA isolation, enabling labs to assess key driver alterations prior to initiating comprehensive genomic profiling, Pillar said.
New York's Memorial Sloan Kettering Cancer Center (MSK) will be the first to use OncoReveal Nexus, branded as MSK-REACT. The new panel, which has received conditional approval from the New York State Department of Health, is expected to help accelerate genomic results in parallel with the comprehensive genomic profiling assay MSK-IMPACT for both solid and hematologic malignancies, Pillar said.
Eurofins Scientific Mplex Mpox, Orthopox Assay
Eurofins Scientific has launched the research-use-only Mplex Mpox, Orthopox assay for the simultaneous qualitative detection and differentiation of the mpox virus from other viruses in the orthopox family. The real-time PCR assay was developed by Gold Standard Diagnostics Frankfurt, a Eurofins company, in response to the 2022 mpox epidemic. The assay has been evaluated and validated by the Institute of Health Carlos III in Spain and the French National Reference Center, Eurofins said. The company added that it is making the assay available to its laboratories worldwide where required and applicable and has set aside test kits for donation to African countries that may need them.
Biognosys NULISA Proteomics Assay Services
Biognosys this week announced the commercial availability of NULISA proteomics assays for biomarker discovery in plasma and other biofluids. NULISA is a highly sensitive proteomics platform developed by Alamar Biosciences and provided by Biognosys under a strategic partnership announced last year. From its Zurich, Switzerland, facility, Biognosys offers Alamar's NULISAseq CNS Disease 120 and Inflammation 250 panels, which are run on the ARGO HT System with the possibility of GCP-compliant and GLP-like lab operation services, enabling exploratory profiling of clinical trial samples. NULISAseq panels are expertly curated to enable multiplexed analysis of previously hard-to-measure cytokines, chemokines, and important disease-specific neurodegeneration markers such as pTau217. The service requires only 10 µl of plasma or other biofluids, Biognosys said.
Cygnus Technologies/TriLink BioTechnologies AccuRes Host Cell DNA Quantification Kits
Cygnus Technologies and TriLink BioTechnologies, both a part of Maravai LifeSciences, have launched AccuRes Host Cell DNA Quantification kits, which use probe-based quantification to ensure specificity for the target host cell line as opposed to off-target DNA. The FAM-labeled nucleic acid probe is quenched by BHQ-1 until PCR extension, and the kits are compatible with any qPCR instrument that detects FAM signal, the companies said. The kit includes all reagents for DNA extraction in a plate or microfuge tube format, AccuRes PCR master mix, primer/probe mix, and a DNA standard. More specifically, the kits combine Cygnus' proprietary extraction procedure with a probe-based master mix containing TriLink's patented CleanAmpdNTPs and a hot-start Taq DNA polymerase. The kits have a demonstrated limit of detection of 0.6 fg/µL, the companies said.
Maine Molecular Quality Controls Xpert PML-RARA Control Panel C215, Xpert PML-RARA Linearity Panel C221
Maine Molecular Quality Controls has introduced new reference material for Cepheid's Xpert PML-RARA assay, the Xpert PML-RARA Control Panel C215, and the Xpert PML-RARA Linearity Panel C221. The promyelocytic leukemia gene (PML) and retinoic acid receptor-α protein (RARA) gene results in PML-RARA, an oncogenic fusion gene, which is a driver for acute promyelocytic leukemia.
The control panel is an external reference material used to monitor the performance of nucleic acid testing procedures for the quantitative detection of PML-RARA transcript isoforms, bcr1, bcr2, bcr3, and ABL1 endogenous control mRNA transcript when analyzed using the Xpert PML-RARA assay on Cepheid's GeneXpert instrument. The linearity panel is intended to monitor the reportable range of nucleic acid testing procedures for the quantitative detection of PML-RARA transcript isoform bcr1 and ABL1 endogenous control mRNA transcript when analyzed with the Cepheid assay.
For more recently launched products and services, please visit the New Products page on our website.